This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Capricor Therapeutics’s 8K filing here.
About Capricor Therapeutics
Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.
Featured Stories
- Five stocks we like better than Capricor Therapeutics
- How to Invest in Small Cap Stocks
- How Whitestone REIT Is Transforming Sun Belt Retail Growth
- The How And Why of Investing in Oil Stocks
- Top-Performing Non-Leveraged ETFs This Year
- How to Read Stock Charts for Beginners
- Rivian’s Wild Ride: Is the Dip a Buying Opportunity?
